Success in treating patients with progressive supranuclear palsy and corticobasal degeneration remains exceedingly low. This finding probably relates to the widespread distribution of the pathological changes that account for the varied and complex spectrum of clinical manifestations. Dopaminergic d
โฆ LIBER โฆ
Behavior and cognition in corticobasal degeneration and progressive supranuclear palsy
โ Scribed by Andrew Kertesz; Paul McMonagle
- Book ID
- 119303528
- Publisher
- Elsevier Science
- Year
- 2010
- Tongue
- English
- Weight
- 198 KB
- Volume
- 289
- Category
- Article
- ISSN
- 0022-510X
No coin nor oath required. For personal study only.
๐ SIMILAR VOLUMES
Treatment of progressive supranuclear pa
โ
Anthony E. Lang
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 230 KB
Ballooned neurons in corticobasal degene
โ
Hideo Mori; Masaya Oda
๐
Article
๐
1997
๐
John Wiley and Sons
๐
English
โ 689 KB
Pathological heterogeneity in progressiv
โ
Koichi Wakabayashi; Hitoshi Takahashi
๐
Article
๐
2004
๐
John Wiley and Sons
๐
English
โ 245 KB
Corticobasal Ganglionic Degeneration and
โ
Catherine Bergeron; Andrea Davis; Anthony E. Lang
๐
Article
๐
2006
๐
John Wiley and Sons
๐
English
โ 188 KB
Neuropathologic differentiation of progr
โ
D. W. Dickson
๐
Article
๐
1999
๐
Springer
๐
English
โ 528 KB
Progressive supranuclear palsy and corti
โ
Tomaso Scaravilli; Eduardo Tolosa; Isidre Ferrer
๐
Article
๐
2005
๐
John Wiley and Sons
๐
English
โ 82 KB
Progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) are both sporadic disorders with tau pathology. Criteria have been defined that in most instances allow for adequate diagnosis of the two disorders both clinically and neuropathologically; however, overlap is not uncommon. For